Last update Aug. 19, 2021
Gold compound with anti-inflammatory properties. Other similar compounds are aurothioglucose and auranofin.
Used as a disease-modifying antirheumatic drug (DMARD) in progressive rheumatoid arthritis and psoriatic arthritis.
Intramuscular administration every 1 to 4-6 weeks.
Aurothiomalate and aurothioglucose are excreted in breast milk in small amounts (Bennett 1990, Rooney 1987, Bell 1976, Sorensen 1970) but this could be clinically significant (Bennett 1990, Blau 1973).
No problems have been observed in infants whose mothers took aurothiomalate (Bennett 1990, Bell 1976). A girl around 18 months of age developed transient facial edema 3 months after the mother’s treatment with aurothiomalate was discontinued (Bell 1976).
The plasma or urine levels of said infants were undetectable or very low (Rooney 1987, Bell 1976), 6 to 22 times lower than maternal serum levels (Bennett 1990).
Expert authors consider the use of gold salts during lactation to be low risk (Ostensen 1992, Needs 1985). Other authors believe that they best be avoided during breastfeeding (Janssen 2000, Byron 1987, Ostensen 1986).
American Academy of Pediatrics: Gold salts are medications usually compatible with breastfeeding (AAP 2001).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM